Award Recognizes the Company’s Verita™ Isolation Platform, which Enables Early-Stage Cancer Detection
Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at their earliest stages, today announced that the Company and its platform technology, Verita™, has been selected as a 2022 finalist by the American Association for Clinical Chemistry (AACC) for their Disruptive Technology Award competition.
“We’re honored to be selected as a finalist by the AACC’s panel for this award, which recognizes the power of our differentiated multiomics platform technology,” said Dr. Paul Billings, CEO and Director of Biological Dynamics. “We are excited to continue building evidence for our first clinical application by enabling the isolation and characterization of exosomes into a unique early-stage cancer detection algorithm and assay.”
The Verita™ Isolation Platform is Biological Dynamics’ proprietary platform, which uses AC Electrokinetics (ACE) technology for isolation of nanoparticles and macromolecules from biofluids, such as whole blood, plasma, serum, urine, and saliva. Using the Verita™ platform, the company recently received an FDA Breakthrough Device Designation for its first liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma using exosomal proteins.
AACC’s Disruptive Technology Award recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. The company was selected based on its technology's clinical validity, patient impact, market opportunity, business model, competitive analysis, intellectual property strength, regulatory plan, team strength, and stage of development.
Biological Dynamics will present their disruptive technology to a panel of expert judges, sponsored by Labcorp and Pall Corporation, on Monday, July 25, at 4:30 p.m. CT at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL. The winner will be announced at the conclusion of the session.
About Biological Dynamics
Biological Dynamics, Inc. is a biotechnology company committed to improving global health outcomes by detecting diseases at their earliest stages. Our proprietary Verita™ platform simplifies access to biomarkers, nanoparticles, and nucleic acids, enabling differentiated multiomic applications. We are applying our proprietary methods with machine learning to detect several diseases, including cancer, in blood and other bodily fluids, at our CAP/CLIA accredited clinical laboratory in San Diego. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005089/en/
Contacts
Kevin Han
Chief Financial Officer
kevin.han@biodyn.io
